ISR’s recent survey of Small Molecule outsourcers found that the majority of respondents outsource for one of two reasons: for all of their manufacturing needs, or to augment their internal manufacturing capacity. However, API outsourcers are more likely to outsource for all of their needs, while drug product outsourcers conversely are more likely to outsource to increase internal capacity. Market access and emergency situations seem to be infrequent drivers for outsourcing across all small molecule manufacturing.

Find more verbatim responses from API and Drug Product outsourcers in our Small Molecule API CDMO Benchmarking (6th Ed.) and Small Molecule Drug Product CDMO Benchmarking (6th Ed.) reports.

Originally published in Life Science Leader.

View File